The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Real-Time Update: Matinas BioPharma Holdings Inc. ...

Real-Time Update: Matinas BioPharma Holdings Inc. (MTNB) Stock Navigates the Market with Up-to-Date Data

The stock of Matinas BioPharma Holdings Inc. (MTNB) has seen a -19.99% decrease in the past week, with a -18.79% drop in the past month, and a -64.84% decrease in the past quarter. The volatility ratio for the week is 14.54%, and the volatility levels for the past 30 days are at 12.24% for MTNB. The simple moving average for the past 20 days is -24.11% for MTNB’s stock, with a -70.48% simple moving average for the past 200 days.

Is It Worth Investing in Matinas BioPharma Holdings Inc. (AMEX: MTNB) Right Now?

Additionally, the 36-month beta value for MTNB is 2.06. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free

The average price predicted by analysts for MTNB is $3.00, which is $2.12 above the current price. The public float for MTNB is 210.93M and currently, short sellers hold a 0.34% ratio of that float. The average trading volume of MTNB on September 18, 2023 was 686.34K shares.

MTNB) stock’s latest price update

Matinas BioPharma Holdings Inc. (AMEX: MTNB) has experienced a decline in its stock price by -15.30 compared to its previous closing price of 0.15. However, the company has seen a fall of -19.99% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-06 that BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

MTNB Trading at -51.10% from the 50-Day Moving Average

After a stumble in the market that brought MTNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.38% of loss for the given period.

Volatility was left at 12.24%, however, over the last 30 days, the volatility rate increased by 14.54%, as shares sank -23.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.07% lower at present.

During the last 5 trading sessions, MTNB fell by -19.99%, which changed the moving average for the period of 200-days by -80.73% in comparison to the 20-day moving average, which settled at $0.1695. In addition, Matinas BioPharma Holdings Inc. saw -73.98% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for MTNB

Current profitability levels for the company are sitting at:

  • -771.33 for the present operating margin
  • +71.83 for the gross margin

The net margin for Matinas BioPharma Holdings Inc. stands at -658.63. The total capital return value is set at -50.21, while invested capital returns managed to touch -43.37. Equity return is now at value -60.90, with -50.20 for asset returns.

Based on Matinas BioPharma Holdings Inc. (MTNB), the company’s capital structure generated 11.26 points at debt to equity in total, while total debt to capital is 10.12. Total debt to assets is 5.23, with long-term debt to equity ratio resting at 9.70. Finally, the long-term debt to capital ratio is 8.72.

When we switch over and look at the enterprise to sales, we see a ratio of 1.11, with the company’s debt to enterprise value settled at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.06.


In conclusion, Matinas BioPharma Holdings Inc. (MTNB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.